AbbVie Hit Harder By EU Humira Biosimilars Than Projected
Executive Summary
The Q3 earnings call was the first time AbbVie management had to face the masses since the mid-October launch of adalimumab biosimilars across Europe. CEO Gonzalez predicted ex-US Humira revenue erosion of 26%-27% this year, higher than previous estimates.
You may also be interested in...
AbbVie’s Downward Humira Guidance Worries Analysts
Decreasing Humira’s ex-US sales guidance for the second time in three months caught significant attention, as AbbVie now expects 30% revenue erosion for its top-seller outside its home market.
Q4 Pharma Earnings Preview: J&J, Bristol And AbbVie
Johnson & Johnson has solid growth drivers in pharmaceuticals, but still faces an overhang related to talc controversy; Bristol's call will be dominated by the just-announced Celgene acquisition; and AbbVie will face questions about its cancer plans after expensive failure with Rova-T.
Pfizer Decides Not To Challenge AbbVie's Humira Biosimilar Patents
Pfizer is the seventh company to enter licensing agreement with AbbVie; it has completed development program for its adalimumab candidate.